2/11/2011 | CVHY | Xoma files $100 million shelf registration covering debt and stock
|
7/23/2010 | PP | New Issue: Xoma arranges $30 million one-year committed equity financing facility
|
7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
6/5/2009 | PP | New Issue: XOMA seals proceeds of $12 million from direct offering of units
|
6/5/2009 | PP | Market Commentary: XOMA plans $12 million direct offering; Proximagen raises £50 million; Alphatec to sell shares
|
5/15/2009 | PP | New Issue: Xoma orchestrates direct offering of equity units for about $10 million
|
5/15/2009 | PP | Market Commentary: GeoPark raises £7.73 million; Mission, Mamut wrap placements; Guyana Goldfields to issue units
|
12/31/2008 | CVHY | XOMA files $150 million shelf registration
|
10/22/2008 | PP | Market Commentary: Xoma takes equity facility; H&R Block sells stock; Xinhua makes convertible deal; Enable sells debentures
|
10/22/2008 | PP | New Issue: Xoma arranges $60 million equity financing facility with Azimuth
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
3/7/2007 | CV | XOMA to automatically convert all $2.5 million convertibles
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
9/7/2006 | BT | XOMA reformulates its topical acne treatment
|
9/6/2006 | BT | XOMA's Neuprex granted orphan status in Europe
|
8/16/2006 | BT | XOMA on hold by Jefferies
|
8/15/2006 | BT | XOMA seeks regulatory approval for Neuprex in United States, Europe
|
7/31/2006 | BT | XOMA gets $16 million biodefense grant for botulism treatment
|
7/28/2006 | BT | XOMA suspends HepeX-B, terminates contract with Cubist
|
7/12/2006 | BT | XOMA to receive new royalty stream from bacterial production license
|
7/11/2006 | BT | Market Commentary: Connetics stock regains 3%; Anadys adds 8% on new exec, moves Idenix, Vertex up, too; Xoma rises 5%
|
7/11/2006 | BT | XOMA expands U.S. government focus
|
5/23/2006 | BT | XOMA, Schering-Plough to develop therapeutic antibodies
|
5/12/2006 | BT | XOMA on hold by Jefferies
|
3/28/2006 | BT | Market Commentary: Advanced Magnetics gains 7%; Xoma slides; Seattle Genetics deal surfaces; Cephalon dips 2%
|
3/15/2006 | BT | Xoma on hold by Jefferies
|
2/9/2006 | BTCV | XOMA exchanges all $60 million 6.5% convertibles due 2012, issues $12 million of new SNAPs
|
1/11/2006 | BTCV | XOMA starts exchange offer for 6.5% convertibles due 2012, offers $10 million of new SNAPs
|
1/5/2006 | BT | Crucell licenses STAR technology to XOMA
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/19/2005 | CV | Market Commentary: Convertibles market mostly quiet; Six Flags edges up, Calpine slips, Albertsons flat
|
12/19/2005 | BTCV | XOMA plans exchange offer for 6.5% convertibles, to sell $10 million of new convertibles
|
9/20/2005 | BT | Xoma kept by Jefferies at hold
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/8/2005 | BT | Xoma maintained by Jefferies at hold
|
8/10/2005 | BT | Xoma maintained by Jefferies at hold
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
6/20/2005 | BT | Market Commentary: HemoSense cuts IPO range; Impax labs, Xoma gain on credit fronts; ImClone up on drug plans
|
5/18/2005 | CV | Market Commentary: Xoma, deCode, Cephalon buyers seen; XM, Sirius at odds in race; Beverly auction in second round
|
4/5/2005 | CV | Market Commentary: Nuveen exchangeables up in gray; El Paso slates preferreds; Mentor Graphics falls on new guidance
|
4/5/2005 | PP | Market Commentary: Eastern Platinum arranges C$30 million offering; Mobility raises $10 million
|
3/14/2005 | CV | Market Commentary: JetBlue a laggard as airline paper up; Delta bankruptcy fears weigh; PDLI gains; Aquila up; Xoma off
|
2/2/2005 | CVPP | New Issue: Xoma sells private placement $60 million convertible at 6.5% yield, up 15%
|
2/2/2005 | CV | Market Commentary: Delta Airlines deal buzz swirls as Pinnacle Airlines soars to 103.5; Tower crumbles to teens on filing
|
2/2/2005 | PP | Market Commentary: Private placements pick up slightly as stocks climb; Guardian plans $20 million deal
|
2/1/2005 | PP | Market Commentary: PIPE volume stalls despite higher stocks; Energy Transfer raises $350 million
|
2/1/2005 | CVPP | XOMA prices $60 million convertibles to yield 6.5%, up 15%
|
1/31/2005 | CVPP | Xoma $60 million private placement convertible talked at 6.0%-6.5% yield, up 22%-28%
|
1/31/2005 | PP | Market Commentary: Private placement volume surges as stocks improve; Xoma plans $60 million offering
|